Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene

Journal of Clinical Investigation

Volumn 98, Issue 5, 1996, Pages 1165-1173

  Del Bufalo, Donatella ^a   Biroccio, Annamaria ^a   Soddu, Silvia ^a   Laudonio, Nina ^a   D'Angelo, Carmen ^a   Sacchi, Ada ^a   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

bcl 2; breast cancer; chemoresistance; DNA fragmentation; glioblastoma

Indexed keywords

CISPLATIN; DOXORUBICIN; LONIDAMINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DEGRADATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029738296     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118900     Document Type: Article

References (55)

1. Van Der Bliek, A.M., and P. Borst. 1989. Multidrug resistance. Adv. Cancer Res. 52:165-168.
2. Ford, J., and W. Hait. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199.
3. Mickisch G., G.T. Merlino, H. Galski, M.M. Gottesman, and I. Pastan. 1991. Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. USA 88:547-551.
4. Citro, G., C. Cucco, A. Verdina, and G. Zupi. 1991. Reversal of ADR resistance by lonidamine in a human breast cancer cell line. Br. J. Cancer. 64:534-536.
5. Floridi, A., A. Gambacurta, A. Bagnato. 1988. Modulation of ADR uptake by LND in Ehrlich ascites tumor cells. Exp. Mol. Pathol. 49:421-431.
6. Silvestrini, R., N. Zaffaroni, R. Villa, L. Orlandi, and A. Costa. 1992. Enhancement of cisplatin activity by LND in human ovarian cancer cells. Int. J. Cancer. 52:813-817.
7. Dogliotti, L., A. Berruti, T. Buniva, P. Zola, M.G. Bau, A. Farris, M.G. Sarobba, A. Bottini, P. Alquati, F. Deltetto, et al. 1996. Lonidamine significantly increased the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. Clin. Oncol. 14: 1165-1172.
8. Floridi, A., and A. Lehninger. Action of the antitumor and antispermatogenic agent LND on electron transport in Ehrlich ascites tumors mitochondria. 1983. Arch. Biochem. Biophys. 226:73-77.
9. Malorni, W., G. Arancia, and C. De Martino. 1988. On the mechanism of action of LND: a study on human erythrocytes membrane. Exp. Mol. Pathol. 49:361-367.
10. Meschini, S., A. Molinari, A. Calcabrini, G. Citro, and G. Arancia. 1994. Intracellular localization of the antitumor drug ADR in living cultured cells: a confocal microscopy study. J. Microsc. (Oxf.). 173:204-210.
11. Barry, M.A., C.A. Behnke, and A. Estman. 1990. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40:2353-2362.
12. Martin, S.J., and T.G. Cotter. 1991. Disruption of microtubules induces an endogenous suicide pathway in human leukemia HL60 cells. Cell Tissue Kinet. 23:545-559.
13. Kaufman, S.H. 1989. Induction of endonucleolytic cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic drugs: a cautionary note. Cancer Res. 49:5870-5878.
14. Ficher, D.E. 1994. Apoptosis in cancer therapy crossing the threshold. Cell. 78:539-542.
15. Fesus, L., P.J.A. Davies, and M. Piacentini. 1991. Apoptosis: molecular mechanism in programmed cell death. Eur. J. Cell. Biol. 56:170-177.
16. Wyllie, A.H. 1987. Apoptosis: cell death in tissue regulation. J. Pathol. 153:313-316.
17. Wyllie, A.H., J.F.R. Kerr, and A.R. Currie. 1980. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251-306.
18. Williams, G.T., and A.C. Smith. 1993. Molecular regulation of apoptosis: genetic controls on cell death. Cell. 74:777-779.
19. Levine, A.J., J. Momand, and C.A. Finlay. 1991. The p53 tumor suppressor gene. Nature (Lond.). 351:453-456.
20. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
21. Hockenbery, D., G. Nunez, C. Milliman, R.D. Scheiberb, and S.J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.). 348:334-336.
22. Strasser, A., A.W. Harris, and S. Cory. 1991. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 67:889-899.
23. Tsujimoto, Y., J. Cossman, E. Jaffe, and C.M. Croce. 1985. Involvement of the bcl-2 gene in human follicular lymphoma. Science (Wash. DC). 228:1440-1443.
24. Yunis, J.J., M.G. Mayer, M.A. Arensen, D.P. Aeppli, M.M. Oken, and G. Frizzera. 1989. Bcl-2 and others' genomic alterations in the prognosis of large-cell lymphomas. N. Engl. J. Med. 320:1047-1054.
25. Wang, Y., L. Szekely, I. Okan, G. Klein, K.G. Wiman. 1993. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 8:3427-3431.
26. Wolf, D., and V. Rotter. 1985. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL60 cells. Proc. Natl. Acad. Sci. USA. 82:790-794.
27. Chang, H., S. Benchimol, M.D. Minden, and H.A. Messner. 1994. Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood. 83:452-459.
28. El-Rouby, S., A. Thomas, D. Costin, C.R. Rosemberg, M. Potmesil, R. Silber, and E.W. Newcomb. 1993. p53 gene mutation in B-cell chronic lymphocityc leukemia is associated with drug resistance and is independent of MDR1/ MDR3 gene expression. Blood. 82:3452-3459.
29. Floridi, A., F.P. Gentile, T. Bruno, M. Fanciulli, M.G. Paggi, M. Zeuli, and M. Benassi. 1990. Cytotoxic effect of the association of BCNU with rhein or lonidamine on a human glioma cell line. Anticancer Res. 11:789-792.
30. Krishnamachary, N., and M. S. Center. 1993. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:3658-3661.
31. Telford, W.G., L.E. King, and P.J. Fraker. 1992. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry. 13:137-143.
32. Fox, M.H. 1980. A model for the computer analysis of synchronous DNA distributions obtained by cytometry. Cytometry. 1:71-75.
33. Martin, S., J.G. Bradley, and T.G. Cotter. 1990. HL60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin. Exp. Immunol. 70:448-453.
34. Kerr, J.F.R., J. Searle, B.V. Harmonand, and C.J. Bishop. 1987. Perspectives on mammalian cells death. Oxford University Press, Oxford, UK. pp 93-128.
35. Skladanowski, A., and J. Konopa. 1993. Adriamycin and Daunumycin induce programmed cell death (apoptosis) in tumor cells. Biochem. Pharmacol. 46:375-382.
36. Soddu, S., G. Blandino, G. Citro, R. Scardigli, G. Piaggio, A. Ferber, B. Calabretta, and A. Sacchi. 1994. Wild-type p53 gene expression induces granulocytic differentiation of HL60 cells. Blood. 83:2230-2237.
37. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p.53. Cell. 62:671-680.
38. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by PI staining and flow cytometry. J. Immunol. Methods. 139:271-279.
39. Rubin, L.L., K.L. Philpott, and S.F. Brooks. 1993. The cell cycle and cell death. Curr. Biol. 3:391-394.
40. Haldar, S., M. Negrini, M. Manne, S. Sabbiani, and C.M. Croce. 1994. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:2095-2097.
41. Kerr, J.F.R., C.M. Winterford, and B.V. Harmon. 1994. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.). 73:2013-2026.
42. Lee, J.M., and A. Bernstein. 1993, p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA. 90:5742-5746.
43. Thompson, A.M., C.M. Steel, U. Chetty, R.A. Hawkins, W.R. Miller, D.C. Carter, A.P. Forrest, and H.J. Evans. 1990. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br. J. Cancer. 61:74-78.
44. Negrini, M., S. Sabbioni, S. Haldar, L. Possati, A. Castagnoli, A. Corallini, G. Barbanti-Brodano, and C.M. Croce. 1994. Tumor and growth suppression of breast cancer cells by chromosome 17 associated functions. Cancer Res. 54:1818-1824.
45. Gottlieb, E., R. Haffner, T. von Ruden, E.F. Wagner, and M. Oren. 1994. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO (Eur. Mol. Biol. Organ.) J. 13:1358-1374.
46. Blandino, G., R. Scardigli, M.G. Rizzo, M. Crescenzi, S. Soddu, and A. Sacchi. 1995. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene. 10:731-737.
47. El-Deiry, W., T. Tokino, V.E., Velculescu, D.B. Levy, R. Parson, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. Waf1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
48. Fan, S., W.S. El-Deiry, I. Bac, J. Freeman, D. Jondle, K. Bhatia, A.J. Fornace, J.I. Magrater, K.W. Kohn, and P.M. O'Connor. 1994. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to damaging agents. Cancer Res. 54:5824-5830.
49. Alnemri, E.S., N.M. Robertson, T.F. Fernandes, and C.M. Croce. 1992. Overexpressed full-length human bcl-2 extends the survival of baculovirus-infected Sf9 insect cells. Proc. Natl. Acad. Sci. USA. 89:7295-7299.
50. Korsmeyer, S.J. 1992. Bcl-2: a repressor of lymphocyte death. Immunol. Today. 13:285-288.
51. Hoyt, D.G. and J.S. Lazo. 1993. NAD depletion after in vitro exposure of murine lung slices to bleomycin. Biochem. Pharmacol. 46:1819-1824.
52. Kaplan, O., G. Navon, R.C. Lyon, J. Faustino, E.J. Strakaand, and J.S. Cohen. 1990. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 50:544-551.
53. Lyon, R.C., J.S. Cohen, P.J. Faustino, F. Megninand, and C.E. Myers. 1988. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res., 48: 870-877.
54. Fanciulli, M., A. Valentini, T. Bruno, G. Citro, U. Zupi, and A. Floridi. 1996. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncology Res. In press.
55. Lotem, J., and L. Sachs. 1993. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 82:1092-1096.